m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00228
 [1], [2], [3], [4], [5]
m6A modification MYC MYC IGF2BP1 : m6A sites Direct Enhancement RNA modification MYC MYC YBX1 : modification sites
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
m6A Target Myc proto-oncogene protein (MYC)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> 5-methylcytidine (m5C)
Epigenetic Regulator Y-box-binding protein 1 (YBX1) READER View Details
Regulated Target Myc proto-oncogene protein (MYC) View Details
Crosstalk Relationship m6A  →  m5C Enhancement
Crosstalk Mechanism m6A modification directly impacts RNA modification through recruiting m6A regulator and targeting the shared RNA
Crosstalk Summary IGF2BP1 recognizes the m6A methylation sites and promotes YBX1-dependent m5C RNA editing of Myc proto-oncogene protein (MYC) transcript.
Responsed Drug AVI-5126
 Drug Info 
Pathway Response Apoptosis hsa04210
Cell Process Cell apoptosis
In-vitro Model
 U2OS Osteosarcoma Homo sapiens CVCL_0042
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
T24 Bladder carcinoma Homo sapiens CVCL_0554
TCCSUP Bladder carcinoma Homo sapiens CVCL_1738
MOLM-13 Adult acute myeloid leukemia Homo sapiens CVCL_2119
THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
HEK293T Normal Homo sapiens CVCL_0063
Kasumi-1 Myeloid leukemia with maturation Homo sapiens CVCL_0589
U-937 Adult acute monocytic leukemia Homo sapiens CVCL_0007
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Myc proto-oncogene protein (MYC) 3 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name AVI-5126 Phase 2 [6]
Synonyms
Resten-CP; NeuGene (CABG), AVI
    Click to Show/Hide
External Link
TTD: D01VDI
 Compound Name Resten-NG Phase 2 [7]
Synonyms
Resten-NG (TN)
    Click to Show/Hide
External Link
TTD: D0M4MG
 Compound Name TWS-119 Investigative [8]
Synonyms
TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB
    Click to Show/Hide
External Link
CID: 9549289
TTD: D0T8KR
References
Ref 1 Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA. 2009 Jan;15(1):104-15. doi: 10.1261/rna.1175909. Epub 2008 Nov 24.
Ref 2 p53-directed translational control can shape and expand the universe of p53 target genes. Cell Death Differ. 2014 Oct;21(10):1522-34. doi: 10.1038/cdd.2014.79. Epub 2014 Jun 13.
Ref 3 YBX1 promotes tumor growth by elevating glycolysis in human bladder cancer. Oncotarget. 2017 Jul 26;8(39):65946-65956. doi: 10.18632/oncotarget.19583. eCollection 2017 Sep 12.
Ref 4 YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021 Jul 8;138(1):71-85. doi: 10.1182/blood.2020009676.
Ref 5 Therapeutic inhibition of GAS6-AS1/YBX1/MYC axis suppresses cell propagation and disease progression of acute myeloid leukemia. J Exp Clin Cancer Res. 2021 Nov 9;40(1):353. doi: 10.1186/s13046-021-02145-9.
Ref 6 Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201. doi: 10.1089/jop.2011.0135. Epub 2011 Dec 7.
Ref 7 Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. doi: 10.1002/ccd.1277.
Ref 8 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.